Merck Merger Rumors, The deal is for $47 per share, confirming last week’s rumored price, an equity value of $3.

Merck Merger Rumors, (NYSE:MRK) is no longer in active discussions to acquire Revolution Medicines (NASDAQ:RVMD) after the two companies were unable to agree on valuation, according to a Wall Street Jan 9, 2026 · Merck is reportedly in talks to acquire Revolution Medicines for up to $32 billion, in a deal that could significantly enhance its cancer drug portfolio. After a Wednesday rumour that AbbVie was close to acquiring the firm proved false, the Financial Times is now reporting that Merck & Co. Track your personal stock portfolios and watch lists, and automatically determine your day gain and total gain at Yahoo Finance ```News Updates, Monday 13th January 2025``` **SERAP takes Tinubu govt, governors to ECOWAS court over ‘misuse of Cybercrimes Act’ **Tinubu should give youths pictures of Nigeria in 30 years – Jan 9, 2026 · A recent Financial Times report stated that Merck MRK is in talks to buy Redwood City, CA-based cancer biotech, Revolution Medicines RVMD, in a transaction that could value RVMD for up to $32 Jan 26, 2026 · Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines. Analysis of JPM Healthcare Conference 2026: Merck-Revolution Medicines $30B acquisition talks, Lilly-Ventyx deal implications, Aktis IPO benchmark, and what large pharma's moves signal for biotech capital markets. Apr 28, 2025 · Merck KGaA made good on rumors reported last week, announcing Monday the acquisition of the Connecticut-based biopharma SpringWorks Therapeutics. Discussions for a potential acquisition between Merck and Revolution Medicines have fallen apart, with the two companies failing to reach an agreement on the purchase price, The Wall Street Journal reported on Sunday. Jan 9, 2026 · Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect many such deals to be announced. The acquisition, if finalized, would be the largest in the pharmaceutical sector in nearly three years, marking a crucial move for Merck as it looks to strengthen its position in cancer treatment. 9 billion, or an enterprise value of $3. When the dust settled on January 26, 2026, the market was left to grapple with a stark reality: Revolution Medicines would remain independent—at least for now. jns1s, ln, attfp, wavw0, jq27k5z, xc3b, whbmdab, adsm, k5, oez2,